Trials / Conditions / Second-line Treatment

Second-line Treatment

12 registered clinical trials studyying Second-line Treatment — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenoca NCT07389876	Fudan University	—
Active Not Recruiting	A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-L NCT07138885	Sun Yat-sen University	Phase 2
Recruiting	Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma NCT06446154	Sun Yat-sen University	Phase 2
Not Yet Recruiting	Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatmen NCT06662877	Sun Yat-sen University	Phase 2 / Phase 3
Not Yet Recruiting	Exercise in Patients With Advanced Non-small Cell Lung Cancer NCT06374160	University Hospital, Essen	N/A
Active Not Recruiting	Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatme NCT06518018	The First People's Hospital of Neijiang	—
Unknown	Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC NCT05901584	Second Affiliated Hospital of Zunyi Medical University	Phase 2
Completed	Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function NCT04522908	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 2
Unknown	Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC NCT04193098	Tianjin Medical University Cancer Institute and Hospital	Phase 1
Completed	A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma NCT03251443	Peking Union Medical College Hospital	Phase 2
Completed	Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer NCT06666582	Hellenic Cooperative Oncology Group	—
Completed	A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-t NCT01379534	Novartis Pharmaceuticals	Phase 2